The Relative Strength (RS) Rating for Vaxcyte moved up into a higher percentile Wednesday, as it got a lift from 69 to 72.
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the top-performing stocks often have an 80 or higher RS Rating in the early stages of their moves. See if Vaxcyte can continue to rebound and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
Vaxcyte has moved more than 5% past a 76.00 entry in a second-stage cup with handle, meaning it's now out of a proper buy zone. Look for the stock to offer a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Vaxcyte showed 0% earnings growth last quarter, while sales growth came in at 0%.
The company holds the No. 248 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, ADMA Biologics and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
